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Background: Heroin’s analgesic, euphoric and dependence-
producing effects are primarily mediated by the mu opioid receptor
(MOR). A single gene, OPRM1, encodes the MOR. The functional
polymorphismA118G, located in exon 1 of theOPRM1 gene, results in
anatomically-specific reductions in MOR expression, which may
alter an individual’s response to heroin. In prior studies 118G
(rare allele) carriers demonstrated significantly greater opioid
tolerance, overdose vulnerability, and pain sensitivity than 118AA
homozygotes. Those findings suggestOPRM1 genotype may impact
characteristics of heroin use.
Methods: The present pilot study characterized the impact of
OPRM1 genotype (rs1799971, 118G allele carriers vs. 118AA
homozygotes) on heroin-use phenotypes associated with heroin
dependence severity in a sample of male, Caucasian chronic heroin
users (n¼ 86).
Results: Results indicate that 118G allele carriers reported signifi-
cantly more heroin use-related consequences and heroin-quit
attempts, and were more likely to have sought treatment for their
heroin use than 118AA homozygotes.
Conclusions: These preliminary findings, consistent with extant
data, illustrate a role for OPRM1 allelic variation on heroin use
characteristics, and provide support for considering genotype in heroin
treatment and relapse prevention. (Am J Addict 2015;24:329–335)
INTRODUCTION
Mu opioid receptors (MORs) mediate most of the clinically
salient effects of heroin (MOR agonist), including analgesia,
euphoria, and depressed respiration.1–3 MOR anatomical
location and post-synaptic connectivity dictate the downstream
effects of a bound agonist. A single gene, OPRM1, encodes the
MOR.4 Variants in the OPRM1 gene can alter opioidergic
function and may therefore impact an individual’s response to
opioid administration. A widely-studied OPRM1 variant is a
single nucleotide polymorphism (SNP) A118G, rs1799971,
resulting in an Asn40Asp amino acid change.4 While the
specific neurobiological effects of this SNP are not fully
understood, data from rodent and human studies suggest the
minor Asp allele is less physiologically functional, though
findings to the contrary5 exist. The 118G variant is associatedwith
diminished mRNA and protein levels in some brain regions.6,7
Using whole brain quantitative autoradiography, Wang et al.8
found diminished MOR expression in the ‘pain matrix’
(cingulate and insular cortices, amygdala and periaqueductal
gray;9–11) and ‘reward centers’ (nucleus accumbens and ventral
tegmental area) of the 112GG homozygote mouse brain (mouse
equivalent of human 118GG homozygotes) compared to 112AA
homozygotes. Mague et al.12 found less morphine-induced
antinociception in 112GG homozygous mice than 112AA
homozygotes. Further, human 118G carriers report less mor-
phine-induced analgesia13–15 and hypersensitivity to nociceptive
stimuli compared to 118AA homozygotes.15,16 Consistentwith the
above findings, Huang et al.17 demonstrated diminished MOR
protein expression in a rodent model of the 118GG genotype, and
Beyer et al.18 andKroslak et al.19 each found human 118G-variant
cell lines demonstrated lower cell-surface MOR agonist binding
capacity (lower Bmax). Further, clinical studies using [
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carfentanil PET imaging found the 118G* genotype was
associated with diminished MOR receptor availability.20,21
Genetic association studies frequently attempt to link
polymorphisms with initial vulnerability to drug dependence.
Coller et al.22 conducted a meta-analysis of 16 studies
examining opioid dependent and control subjects (>5000
subjects) and found no link between OPRM1 rs1799971
genotype and opioid dependence. Arias et al.23 conducted a
meta-analysis of 22 published studies investigating risk of
substance dependence byOPRM1 rs1799971 genotype across
ethnicities (>8000 subjects) and drugs of abuse (alcohol,
heroin, opioids, and cocaine); they found no link between
genotype and substance dependence, nor did they find any
significant relationships between ethnicity, genotype and
dependence. Haerian andHaerian24 conducted ameta-analysis
of 18 studies (>8000 subjects) and found no association
between OPRM1 rs1799971 genotype and opioid/cocaine or
heroin dependence in African-American or Caucasian sub-
jects, but opioid-dependent Asian subjects (among whom the
118G variant is more prevalent: 40–50% vs. 15–30% in
Caucasians and 1–3% in African-Americans;25) were more
likely to be 118G carriers than 118AA homozygotes.
However, genetic factors likely influence all phases of drug
dependence, not solely vulnerability to dependence.26 Nikolov
et al.27 hypothesized that the 118G variant may not impact risk
for but, rather, severity of heroin dependence. In support of
this hypothesis, heroin-dependent 118G carriers demonstrated
enhanced heroin tolerance (in haplotype with IVS2þ 31 G/A
variant;28) and 5.3 greater risk of cardiac or respiratory
arrest29 than 118AA homozygotes. Diminished MOR expres-
sion in analgesia- and euphoria-mediating brain regions8,30
may explain 118G carriers’ enhanced opioid tolerance13–15,28
and pain sensitivity.15,16 Exaggerated pain sensitivity and
enhanced opioid tolerance may lead users to self-administer
heroin via a more pharmacokinetically-efficient route (e.g.,
injection vs. insufflation), use more frequently, or consume
larger doses to achieve the desired effects, thereby increasing
risk of overdose and respiratory/cardiac arrest.29
In the present study, we examined heroin use phenotypes
associated with heroin dependence severity by A118G
genotype in chronic, regular Caucasian male heroin users
not currently seeking treatment. Consistent with Nikolov
et al.27, we hypothesized 118G carriers would report heroin use
characteristics indicative of greater severity of heroin depend-
ence including: more lifetime heroin use consequences
(specifically overdose), lifetime heroin quit attempts, and
frequent current heroin use, and greater likelihood of having
sought treatment for their heroin use and self-administering
heroin via injection than 118AA homozygotes.
MATERIALS AND METHODS
Participants
This retrospective investigation utilized screening data
obtained from four source studies approved by Institutional
Review Boards at Wayne State University and the University
of Michigan (for methodological details see: 31–34), and was
conducted in accordance with the Declaration of Helsinki
(1964).35 The National Institute on Drug Abuse issued
certificates of confidentiality for these studies. Participants
were recruited from the Detroit, Michigan metropolitan
area using print media advertisements and word-of-mouth
referral.
Individuals identifying themselves as regular heroin users and
not seeking treatment completed a brief phone screen. Eligible
individuals were scheduled for an in-person screening interview.
Volunteers provided informed consent, demographic data, and
comprehensive substance use and medical histories. Current
heroin use was confirmed by opioid-positive urine sample
(>300 ng/ml). Participants were sober (<.002% expired blood
alcohol content) during the intake interview. Completion of the
screening visit earned each participant a $30 check.
Genotyping
Plasma samples were collected (6ml per participant) in
EDTA tubes. Participant DNA was extracted using the
Qiagen kit (formerly Gentra Puregene) and genotyped using
the Taqman assay according to the manufacturer’s
conditions and solutions (Applied Biosystems ABI, Foster
City, CA). Additionally, a subset of participant DNA
samples were genotyped using Illumina Golden Gate
addiction panel.35 The two assays were in complete
agreement for OPRM1 rs1799971 genotype for this sample.
The Golden Gate panel has the advantage of including 186
ancestry informative markers (AIMs) that were used to
evaluate racial stratification and confirm self-reported
racial identity from the full sample of source study
participants, which included African- Americans and
Caucasians only (n¼ 186). Principal component analyses
were conducted (forcing a two-factor solution with a
Varimax rotation) with the 150 AIMs containing at least
90% genotype data and a factor loading coefficient .30
which revealed complete separation between races and no
overlapping cases (Fig. 1). These analyses supported the
self-reported racial identities and indicated the presence of
genetically-distinct groups.
A common OPRM1 SNP occurs at position 118
(rs1799971) in exon 1 (adenine-to-guanine substitution:
A118G) encoding an asparagine-to-aspartic acid amino acid
exchange (N40D) in the N-terminal domain.4 Due to scarcity
of the OPRM1 118GG genotype and scarcity of the G allele in
African-Americans, analyses presented herein contrasted
Caucasian 118G carriers (118GG and 118AG) with 118AA
homozygotes. Indeed, of the 131 African-American individ-
uals available for analysis, only five were 118G carriers:
insufficient for outcome analyses.
Phenotyping
Heroin-use phenotypes were derived from a comprehen-
sive, standardized self-report substance use history ques-
tionnaire routinely used in our laboratory. Analyses focused
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on five dependent variables: current heroin administration
route (injection vs. non-injection), past-month heroin use
frequency, lifetime number of heroin use-related conse-
quences, lifetime number of attempts to quit using heroin,
and having ever sought treatment for heroin use. Current
route of self-administration, lifetime treatment for heroin
use, and lifetime number of attempts to quit (with and
without treatment) using heroin were assessed via single-
item face-valid self-report variables. Past-month heroin use
frequency was calculated as a product score of past-week
mean daily use multiplied by number of days using heroin in
the past month. Heroin use consequences were assessed via a
21-item questionnaire (see Table 2). Items parallel SCID
symptom checklists and encompass potential heroin use-
related consequences. Participants were asked to indicate
(present/absent) each consequence they experienced as a
direct result of their heroin use. Endorsed consequences were
summed for analysis of total consequences (outcome
measure); however, individual item endorsement was also
explored to better understand the effects of A118G genotype
on heroin use consequences.
Data Analyses
Distributions of continuous variables were evaluated for
skewness and kurtosis36 to assess normality prior to outcome
analyses. The only non-normal distribution was lifetime
heroin quit attempts (positively skewed), which was normal-
ized using a square root transformation. Unequal sample sizes
across genotype increased our risk of Type I error. To protect
against Type I error inflation, Levene’s Test of Equality of
Error Variances was used to confirm (all p values >.50)
homogeneity of variance for each outcome variable in our
analyses.
All analyses were conducted using SPSS version 22 with
the criterion to reject the null hypothesis set at p.05. Fisher’s
Exact and Chi Square tests were performed to assess the
distribution of genotype by route of heroin administration
(injection vs. non-injection), seeking treatment for heroin use,
and individual items in the heroin use consequences survey.
Continuous variables (e.g., past-month heroin use frequency)
were evaluated using one-way Analyses of Variance
(ANOVAs) to compare genotype effects. Number of lifetime
heroin use consequences and quit attempts are likely to
accumulate with longer duration of heroin use, which could
bias interpretation of results. If these variables were positively
correlated, analysis of covariance (ANCOVA), with years of
heroin use entered as a covariate, was used in analyses.
Descriptive statistics are presented as mean (M) one
standard deviation (SD).
RESULTS
Participant Characteristics
All participants (n¼ 86 Caucasian males) were current
(opioid positive urine sample; >300 ng/ml) and chronic
[M 1 SD¼ 14.2 10.2 years] heroin users who were not
currently seeking treatment. The average participant was
37.7 10.0 years old with 12.3 1.5 years of formal
education. All participants reported regular heroin use, defined
as >3 uses during the past week. 118G carriers were
significantly younger than 118AA homozygotes, F(1,
85)¼ 6.28, p< .05 [32.6 9.7 vs. 39.1 9.8 years old], but
did not differ (p> .25) by years of education [12.7 1.6 vs.
12.2 1.5 years old].
Genotype Associated With Heroin Use
Characteristics
Heroin use data are presented in Table 1. Fisher’s Exact
Test (FET) revealed current route of heroin administration
(injection vs. non-injection) was not significantly associated
with genotype [100% of 118G carriers vs. 86.8% of 118AA
homozygotes injected heroin, p¼ .08; FET one-tailed;
Cramer’s V¼ .19 (small-to-moderate effect size)].
Chi-square analyses indicated 118G carriers were signifi-
cantly more likely (88.9% vs. 61.8%) to report having sought
treatment for their heroin use at some point during their
lifetime than 118AA homozygotes [x2(1)¼ 4.77, p< .05]. Two
thirds of participants (67.4%) reported seeking treatment for
their heroin use, which was unrelated to duration of their
heroin use, F(1, 85)¼ 0.93, p¼ .34.
Past-month heroin-use frequency was not correlated with
duration of heroin use (r¼ -.15; p¼ .16) and thus, ANOVA
was used to evaluate the effect of genotype on use frequency.
118G carriers did not report significantly different past-month
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FIGURE1. Self-reported racial identification (African-American vs.
Caucasian) stratified by principal component factor loading.
Principal component analysis of the 150 ancestry informative
markers (AIMs) with >90% genotype data for this sample and a
factor loading coefficient .30 revealed complete separation
between races. These analyses indicated that self-reported racial
identity agrees with AIMs and argued against racial stratification
being a primary study confound.
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heroin use than 118AA homozygotes, F(1, 84)¼ 1.95, p¼ .17
[126.8 66.1 vs. 101.6 68.5].
As expected, number of heroin quit attempts and years
using heroin (duration) were positively correlated (r¼ .35,
p< .001); thus, number of years using heroin was entered as a
covariate. ANCOVA indicated genotype was significantly
associated with heroin quit attempts, F(1, 85)¼ 3.92, p¼ .05;
partial eta-squared [h2]¼.045. 118G carriers reported nearly
twice as many heroin quit attempts as AA homozygotes
[19.1 30.4 vs. 11.0 20.9].
Lifetime heroin use consequences were positively corre-
lated with number of years using heroin (r¼ .39, p< .01);
again, as anticipated, the latter variable was entered as a
covariate in analyses. ANCOVA revealed genotype was
significantly associated with heroin-use consequences, F(1,
85)¼ 4.47, p< .05; h2¼.051. 118G carriers reported more
lifetime heroin use consequences than AA homozygotes
[11.1 4.2 vs. 9.2 4.7].
Item-level endorsements of lifetime heroin use con-
sequences are presented in Table 2. Chi-square analyses
revealed item-level differences between genotypes: 118G
carriers endorsed ‘overdose’ (66.7% vs. 33.8%), ‘seizure/
fits’ (16.7% vs. 2.9%), and ‘high at work’ (100.0% vs.
76.1%) significantly more frequently than 118AA homo-
zygotes [x2(1)¼ 6.36, p< .05, x2(1)¼ 4.90, p< .05, and
x2(1)¼ 5.30, p< .05; respectively]. Although every 118G
carrier in this sample endorsed they ‘couldn’t stop using’
heroin, this item did not significantly differ by genotype
[100.0% vs. 85.3%; x2(1)¼ 3.00, p¼ .08]. No other items
approached significance (p values > .10).
Behavioral Associations Unrelated to Genotype
Lifetime quit attempts and heroin use consequences were
positively correlated (r¼ .31, p< .01). Number of heroin use
consequences (but not quit attempts or use frequency,
ps> .10) differed by current heroin administration route,
F(1, 85)¼ 11.67, p< .001, while controlling for duration of
heroin use. Those who currently injected heroin endorsed
significantly more lifetime heroin use consequences than those
who did not inject heroin [10.1 4.5 vs. 5.7 3.7].
DISCUSSION
The current study contrasted clinically-relevant heroin use
characteristics by OPRM1 rs1799971 genotype (118G carriers
vs. 118AA homozygotes) in a non-treatment-seeking sample of
chronic, regular Caucasian male heroin users. We hypothe-
sized 118G carriers would report heroin use characteristics in
support of Nikolov and colleagues27 hypothesis that the 118G
allele is associated with more ‘severe’ opioid dependence.
118G carriers reported more lifetime heroin-use consequences,
quit attempts and were more likely to have sought treatment
for their heroin use, relative to 118AA homozygotes. However,
there were no genotype differences in reported past-month
heroin use frequency or current route of self-administration.
These preliminary findings provide initial evidence that the
OPRM1 118G variant may be associated with more burden-
some outcomes from chronic heroin use.
118G carriers reported more lifetime heroin-use consequen-
ces than 118AA homozygotes (endorsing 11 vs. 9 of the 21
possible consequences). Rather than being a simple count of
potentially redundant episodes of dysfunctional behavior and
adverse events, these data indicate 118G carriers experienced a
more expansive range of heroin use-related consequences.
Clinical and preclinical studies6–8,17,20,21,30 indicate the 118G
allele may be less physiologically functional, resulting in
anatomically-specific diminishedMOR availability associated
with increased pain sensitivity and opioid tolerance.13–16,28
Considering these findings, we hypothesized that heroin may
be less potent or have lower intrinsic efficacy in 118G carriers,
who may therefore self-administer larger doses to achieve
desired effects, thereby enhancing risk of overdose. We could
not collect accurate data on heroin dosage sowewere unable to
test this hypothesis directly. However, item-level analyses of
heroin use consequences confirm that 118G carriers were more
likely to report ‘overdose’ and ‘seizures/fits’ from heroin use
than 118AA homozygotes, providing indirect support for this
hypothesis. These data are consistent with Manini et al.29
indicating the 118G variant conveyed a 5.3-fold greater risk of
cardiac or respiratory arrest from heroin overdose. 118G
carriers reported having been ‘high at work’ more frequently,
which was unexpected, but consistent with the working
TABLE 1. Heroin use characteristics
118AA (n¼ 68) M ( 1 SD) 118G* (n¼ 18) M ( 1 SD) F or x2 Cohen’s d
Age at First Use 24.4 (7.2) 20.9 (4.4) 3.78 0.53
Years of Use 14.8 (10.4) 11.7 (9.2) 1.32 0.31
Use Frequency 101.6 (68.5) 126.8 (66.1) 1.95 0.37
Use Consequences# 9.2 (4.7) 11.1 (4.2) 4.47* 0.42
Quit Attempts# 11.0 (20.9) 19.1 (30.4) 3.92* 0.35
Route (% inject) 85.3% 100.0% 2.66 –
Sought Treatment (%) 61.8% 88.9% 4.77* –
#Indicates ANCOVA was performed with duration of heroin use entered as covariate. Significant differences indicated: *p .05.
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hypothesis. Finally, 118G carriers were not statistically
(p¼ .08) more likely to report they ‘couldn’t stop using’
than 118AA homozygotes, though a ceiling effect is possible
(100% of 118G carriers endorsed they ‘couldn’t stop using’
heroin).
118G carriers reported significantly more lifetime attempts
to quit using heroin than 118AA homozygotes, controlling for
years of heroin use. Given that study participants were current
heroin users, these prior quit attempts were by definition
unsuccessful. While these data cannot address the temporal (or
causal) relationship between heroin-quit attempts and use
consequences, these variables are significantly positively
correlated. Moreover, 118G carriers were significantly more
likely to have sought past treatment for their heroin use than
118AA homozygotes.
All 118G carriers (100%) reported current self-
administration of heroin via injection (vs. non-injection),
but not statistically more than 118AA homozygotes (86.8%;
possible ceiling effect). Injection is a more efficient and
dangerous drug delivery route compared to snorting or
smoking, and is associated with more rapid progression to
dependence,37 more severe heroin dependence, quicker
relapse, and worse opioid withdrawal symptoms.38–40
Some limitations of the present study are important to note.
First, this pilot investigation used a small convenience sample.
Thus, the present results should be interpreted with caution
and would benefit from replication in a larger sample.
However, the specific a priori selection of the A118G
polymorphism for analysis, our hypothesis-driven analytic
approach, demographic homogeneity of the sample, and
moderate effect sizes compensated for the limited statistical
power and revealed several significant differences by
genotype. Second, while some of the present findings support
Nikolov and colleagues27 working hypothesis, these findings
are not conclusive. Indeed, several of our hypotheses were not
supported by the data: 118G carriers did not report more
frequent heroin use or higher rates of injection (possibly due to
a ceiling effect). Third, reliance on self-report data is a
limitation in the current study. Fourth, while some participants
did report poly-substance use, and previous findings indicate
the A118G polymorphism is related to alcohol use phenotypes,
this sample is composed of primary heroin users and thus
analyses focused solely on heroin use-related phenotypes.
Finally, due to scarcity of the 118G allele, we focused on a
demographically-homogenous sample (Caucasian males) for
three reasons. First, the A118G polymorphism is infrequent
among African-Americans (only five 118G carriers in
our sample; 3.8%), which is consistent with the literature
(1–3%;25). Second, meta-analyses indicate ethnicity may be
related to dependence.24 Third, extant research suggests there
may be gender-specific effects of the A118G genotype on
substance use characteristics,41–43 pain threshold,44 and opioid
response.12 Despite our interest in examining possible gender
effects in heroin use characteristics, there were too few female
TABLE 2. Heroin use consequences item endorsement
Item (% Endorsed) Overall (n¼ 86) 118AA (n¼ 68) 118G* (n¼ 18) x2
Instructions: In your opinion, have you had any of these problems because you took heroin? If you have, please mark each
below:
Unexpected reaction 35.3% 32.8% 44.4% 0.84
Overdose 40.7% 33.8% 66.7% 6.36*
Memory lapse 31.4% 32.4% 27.8% 0.14
Seizure/fits 5.8% 2.9% 16.7% 4.90*
Shakes/tremors 31.8% 32.4% 29.4% 0.05
Couldn’t stop using 88.4% 85.3% 100.0% 3.00
Arrested/legal problems 45.3% 45.6% 44.4% 0.01
Accident/injury 17.4% 19.1% 11.1% 0.63
Health problem 30.2% 30.9% 27.8% 0.07
High at work 81.2% 76.1% 100.0% 5.30*
Lost job 57.6% 55.2% 66.7% 0.76
Missed work 67.4% 64.7% 77.8% 1.11
Got warning or disciplined at work 43.0% 41.2% 50.0% 0.45
High at school 25.6% 22.1% 38.9% 2.12
Missed school 20.9% 17.6% 33.3% 2.12
Suspended or expelled from school 10.5% 10.3% 11.1% 0.01
Fight or quarrel 33.7% 29.4% 50.0% 2.70
Drove under influence 87.2% 85.3% 94.4% 1.07
Family problems 87.2% 85.3% 94.4% 1.07
Financial problems 95.3% 95.6% 94.4% 0.04
Visited Emergency Room 34.3% 32.7% 40.0% 0.28
*Indicates significant difference between OPRM1 118AA and 118G carrier genotypes (p< .05).
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118G carriers (n¼ 7) available to address this issue. Finally,
some findings presented here would not survive multiple
comparison correction for the variants tested, and hence
should be considered hypothesis-generating.
With these caveats in mind, the present findings offer initial
support that A118G genotype may influence heroin use
characteristics relevant to treatment efficacy in opioid
dependent individuals. 118G carriers reported experiencing
more heroin use consequences indicative of greater psycho-
social dysfunction and possible health problems (e.g.,
‘seizure/fits’, ‘high at work’, ‘overdose’), which may
complicate and prolong treatment (i.e., necessitating a higher
level of care). All 118G carriers reported currently injecting
heroin, thereby increasing risk of contracting blood borne
viruses or developing infections from shared and/or unclean
syringes. Finally, 118G carriers were more likely to have
sought treatment in the past and reported more lifetime
attempts (i.e., prior failures) to abstain from heroin use, which
may reflect greater susceptibility to relapse. Taken together,
these findings highlight the importance of, and potential role
for, considering OPRM1 genotype in opioid dependence
treatment.
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